← Open Payments lookup

NPI 1780750299: Open Payments

NPI 1780750299. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,423 in 84 payments from 10 companies in 2025. Trend: 2023 $1,014 · 2024 $1,938 · 2025 $1,423

Food & beverage: $1,423
CompanyPaymentsAmount
ABBVIE INC.28$301
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)11$284
Otsuka America Pharmaceutical, Inc.15$212
Alkermes, Inc.7$141
Lundbeck LLC6$140
Vanda Pharmaceuticals Inc.9$140
Janssen Pharmaceuticals, Inc3$101
Axsome Therapeutics, Inc.3$64
Teva Pharmaceuticals USA, Inc.1$22
Takeda Pharmaceuticals U.S.A., Inc.1$18

Products named: REXULTI, VRAYLAR, CAPLYTA, FANAPT, INVEGA SUSTENNA, ARISTADA, LYBALVI, Auvelity.